Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05495776 | Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer(MSIRus22) | recruiting | — | 2,500 | State Scientific Centre of Coloproctology, Russian FederationOTHER_GOV | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05585554 | Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy(LAP-ABLATE) | not yet recruiting | N/A | 267 | Viewray Inc. |
| 0 |
| Oct 19, 2022 |
| clinicaltrials |
| NCT03621644 | Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer | active not recruiting | N/A | 133 | Viewray Inc.INDUSTRY | 2 | Oct 14, 2022 | clinicaltrials |
| NCT05579353 | The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer | recruiting | — | 200 | Jingbo ChenOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT04527861 | Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer(CSILS) | recruiting | N/A | 710 | Ruijin HospitalOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT05427669 | Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)(AFFORD) | not yet recruiting | Phase 3 | 340 | Yanhong DengOTHER | 0 | Oct 7, 2022 | clinicaltrials |
| NCT05566249 | A Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center Registry | recruiting | — | 1,000 | Samsung Medical CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT04280822 | Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma | recruiting | Phase 3 | 400 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05547529 | The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer | recruiting | Phase 3 | 156 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03747588 | The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer(MIOPP) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05563922 | Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma(OP-TNT) | recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04673955 | BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment(BERING-CRC) | recruiting | — | 500 | Pierre Fabre Pharma GmbHINDUSTRY | 2 | Sep 29, 2022 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05528783 | Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance | recruiting | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05541601 | Prospective Cohort for Early Detection of Liver Cancer(Pearl) | recruiting | — | 3,000 | University of OxfordOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05537129 | Laparoscopic vs Open Total Gastrectomy for Gastric Cancer | recruiting | N/A | 600 | Fudan UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05534906 | The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) | recruiting | — | 250 | University of OxfordOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT05529615 | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer(CTAC) | recruiting | N/A | 2,684 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05531045 | 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma(TEP-PREDICT) | not yet recruiting | — | 222 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04389086 | Induction Chemotherapy for Locally Recurrent Rectal Cancer(PelvEx II) | recruiting | Phase 3 | 364 | Catharina Ziekenhuis EindhovenOTHER | 5 | Sep 6, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | not yet recruiting | Phase 2 | 203 | Fujian Medical UniversityOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04893876 | The OPERa Study: Evaluating QoL After Rectal Cancer Surgery | not yet recruiting | — | 1,200 | Jewish General HospitalOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05434026 | Chinese Colorectal Cancer Database(CCCD) | recruiting | — | 200,000 | Beijing Friendship HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05484024 | Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 588 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05447611 | Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.(EMPACOL) | not yet recruiting | — | 250 | University Hospital, CaenOTHER | 0 | Jul 7, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05429216 | Endoscopic Resection for Small Rectal Neuroendocrine Tumors | not yet recruiting | N/A | 102 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420480 | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy | not yet recruiting | N/A | 323 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05426135 | Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05396560 | Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy(FIT2RUN) | recruiting | — | 3,000 | University of CalgaryOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05369117 | Application of Indocyanine Green Labeled Fluorescent Laparoscopy in Proximal Gastric Cancer | not yet recruiting | N/A | 1,016 | Guangyong ZhangOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05364489 | Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 20, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05182944 | A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC | recruiting | Phase 2 | 130 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05239650 | Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | not yet recruiting | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT05356156 | The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy | not yet recruiting | N/A | 1,968 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT03972956 | Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease | recruiting | — | 1,000 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05323929 | The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma | recruiting | N/A | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2022source: clinicaltrials